Plain-English translation of NCT07616440 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new approach that combines focused ultrasound (sound waves directed at the tumor) with SonoVue® to help deliver cancer-fighting chemotherapy more directly to breast cancer cells. The study wants to see if adding this sound-wave technology to standard chemotherapy before surgery helps more tumors shrink completely. Researchers will compare how well this new combined approach works compared to standard chemotherapy alone.
HER2-positive breast cancer is an aggressive type that needs strong treatment, but not all patients respond the same way to standard chemotherapy. This medication aims to help chemotherapy drugs reach cancer cells more effectively, potentially improving outcomes for patients who might otherwise have less response to treatment.
You likely qualify if…
You likely don't qualify if…
You would receive the standard chemotherapy regimen your doctors planned, plus the addition of focused ultrasound treatment sessions combined with SonoVue® during your chemotherapy. The study team will monitor you closely with blood tests, imaging, and heart function checks to ensure safety. After completing chemotherapy, you'll have surgery as planned, and researchers will examine whether the tumor responded completely to the treatment.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China